{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:12:53Z","timestamp":1790190773280,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,8,5]],"date-time":"2011-08-05T00:00:00Z","timestamp":1312502400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1471-2377-11-97","type":"journal-article","created":{"date-parts":[[2011,8,5]],"date-time":"2011-08-05T18:27:50Z","timestamp":1312568870000},"source":"Crossref","is-referenced-by-count":100,"title":["A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis"],"prefix":"10.1186","volume":"11","author":[{"given":"Jeannine M","family":"Heckmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanullah","family":"Rawoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudi","family":"Renison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motasim","family":"Badri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,8,5]]},"reference":[{"key":"503_CR1","first-page":"CD005224","volume-title":"Cochrane Database Syst Rev","author":"IK Hart","year":"2007","unstructured":"Hart IK, Sathasivam S, Sharshar T: Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev. 2007, CD005224-"},{"issue":"5","key":"503_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB: Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009, 8 (5): 475-90. 10.1016\/S1474-4422(09)70063-8.","journal-title":"Lancet Neurol"},{"key":"503_CR3","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B: A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology. 1998, 50: 1778-83.","journal-title":"Neurology"},{"key":"503_CR4","first-page":"959","volume":"97","author":"KJ Bateman","year":"2007","unstructured":"Bateman KJ, Schinkel M, Little F, Liebenberg L, Vincent A, Heckmann JM: Incidence of seropositive myasthenia gravis in Cape Town and South Africa. S Afr Med J. 2007, 97: 959-62.","journal-title":"S Afr Med J"},{"key":"503_CR5","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1212\/01.WNL.0000098887.24618.A0","volume":"61","author":"DP Richman","year":"2003","unstructured":"Richman DP, Agius MA: Treatment of autoimmune myasthenia gravis. Neurology. 2003, 61: 1652-61.","journal-title":"Neurology"},{"key":"503_CR6","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1136\/ard.2008.092668","volume":"68","author":"K Visser","year":"2009","unstructured":"Visser K, van der Heijde D: Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis. 2009, 68: 1094-99. 10.1136\/ard.2008.092668.","journal-title":"Ann Rheum Dis"},{"key":"503_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000113809","volume":"2","author":"HG Mertens","year":"1969","unstructured":"Mertens HG, Balzereit F, Leipert M: The treatment of severe myasthenia gravis with immunosuppressive agents. Eur Neurol. 1969, 2: 321-39. 10.1159\/000113809.","journal-title":"Eur Neurol"},{"key":"503_CR8","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/archneur.59.5.739","volume":"59","author":"JN Pruitt","year":"2002","unstructured":"Pruitt JN, Swift TR: Therapies for disorders of the neuromuscular junction. Arch Neurol. 2002, 59: 739-42. 10.1001\/archneur.59.5.739.","journal-title":"Arch Neurol"},{"key":"503_CR9","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/mus.20030","volume":"29","author":"JC Keesey","year":"2004","unstructured":"Keesey JC: Clinical evaluation and management of myasthenia gravis. Muscle Nerve. 2004, 29: 484-505. 10.1002\/mus.20030.","journal-title":"Muscle Nerve"},{"key":"503_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/jnnp.2007.134130","volume":"7","author":"D Hilton-Jones","year":"2007","unstructured":"Hilton-Jones D: When the patient fails to respond to treatment: myasthenia gravis. Pract Neurol. 2007, 7: 405-11. 10.1136\/jnnp.2007.134130.","journal-title":"Pract Neurol"},{"key":"503_CR11","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/art.1780340805","volume":"34","author":"ME Jeurissen","year":"1991","unstructured":"Jeurissen ME, Boerbooms AM, van de Putte LB, et al: Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight-week randomized, double-blind trial. Arthritis Rheum. 1991, 34: 961-72. 10.1002\/art.1780340805.","journal-title":"Arthritis Rheum"},{"key":"503_CR12","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1093\/rheumatology\/32.8.751","volume":"32","author":"P Seideman","year":"1993","unstructured":"Seideman P: Methotrexate--the relationship between dose and clinical effect. Br J Rheumatol. 1993, 32: 751-53. 10.1093\/rheumatology\/32.8.751.","journal-title":"Br J Rheumatol"},{"key":"503_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/BF00302669","volume":"14","author":"A Schnabel","year":"1994","unstructured":"Schnabel A, Reinhold-Keller E, Willmann V, Gross WL: Tolerability of methotrexate starting with 15 or 25 mg\/week for rheumatoid arthritis. Rheumatol Int. 1994, 14: 33-8. 10.1007\/BF00302669.","journal-title":"Rheumatol Int"},{"key":"503_CR14","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1590-8658(03)00372-4","volume":"35","author":"S Ardizzone","year":"2003","unstructured":"Ardizzone S, Bollani S, Manzionna G, Imbesi V, Colombo E, Bianchi Porro G: Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig Liver Dis. 2003, 35: 619-27. 10.1016\/S1590-8658(03)00372-4.","journal-title":"Dig Liver Dis"},{"key":"503_CR15","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","volume":"841","author":"RJ Barohn","year":"1998","unstructured":"Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW: Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci. 1998, 841: 769-72. 10.1111\/j.1749-6632.1998.tb11015.x.","journal-title":"Ann N Y Acad Sci"},{"key":"503_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki","year":"2000","unstructured":"Jaretzki A, Barohn RJ, Ernstoff RM, et al: Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000, 55: 16-23.","journal-title":"Neurology"},{"key":"503_CR17","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ: Myasthenia gravis activities of daily living profile. Neurology. 1999, 52: 1487-89.","journal-title":"Neurology"},{"key":"503_CR18","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.nmd.2007.07.002","volume":"17","author":"JM Heckmann","year":"2007","unstructured":"Heckmann JM, Owen EP, Little F: Myasthenia gravis in South Africans: racial differences in clinical manifestations. Neuromuscul Disord. 2007, 17: 929-34. 10.1016\/j.nmd.2007.07.002.","journal-title":"Neuromuscul Disord"},{"key":"503_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jneuroim.2008.05.031","volume":"201-202","author":"IB Aban","year":"2008","unstructured":"Aban IB, Wolfe GI, Cutter GR, et al: The MGTX experience: challenges in planning and executing an international, multicenter clinical trial. J Neuroimmunol. 2008, 201-202: 80-84.","journal-title":"J Neuroimmunol"},{"key":"503_CR20","doi-asserted-by":"publisher","first-page":"695","DOI":"10.7326\/0003-4819-134-8-200104170-00013","volume":"134","author":"JM Kremer","year":"2001","unstructured":"Kremer JM: Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med. 2001, 134: 695-706.","journal-title":"Ann Intern Med"},{"key":"503_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/anr.1780320202","volume":"32","author":"JM Kremer","year":"1989","unstructured":"Kremer JM, Lee RG, Tolman KG: Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples. Arthritis Rheum. 1989, 32: 121-7. 10.1002\/anr.1780320202.","journal-title":"Arthritis Rheum"},{"key":"503_CR22","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJM198703193161205","volume":"316","author":"RS Tindall","year":"1987","unstructured":"Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G: Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med. 1987, 316: 719-24. 10.1056\/NEJM198703193161205.","journal-title":"N Engl J Med"},{"key":"503_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M: Lifetime course of myasthenia gravis. Muscle Nerve. 2008, 37: 141-9. 10.1002\/mus.20950.","journal-title":"Muscle Nerve"},{"key":"503_CR24","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/ard.62.5.423","volume":"62","author":"M Hoekstra","year":"2003","unstructured":"Hoekstra M, van Ede AE, Haagsma CJ, et al: Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis. 2003, 62: 423-6. 10.1136\/ard.62.5.423.","journal-title":"Ann Rheum Dis"},{"key":"503_CR25","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7","volume":"44","author":"AE van Ede","year":"2001","unstructured":"van Ede AE, Laan RF, Rood MJ, et al: Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001, 44: 1515-24. 10.1002\/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7.","journal-title":"Arthritis Rheum"},{"key":"503_CR26","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1365-2133.2008.08876.x","volume":"160","author":"S Prey","year":"2009","unstructured":"Prey S, Paul C: Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol. 2009, 160: 622-8. 10.1111\/j.1365-2133.2008.08876.x.","journal-title":"Br J Dermatol"},{"key":"503_CR27","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1172\/JCI2676","volume":"102","author":"L Genestier","year":"1998","unstructured":"Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP: Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest. 1998, 102: 322-8. 10.1172\/JCI2676.","journal-title":"J Clin Invest"},{"key":"503_CR28","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.4049\/jimmunol.167.5.2911","volume":"167","author":"S Majumdar","year":"2001","unstructured":"Majumdar S, Aggarwal BB: Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation. J Immunol. 2001, 167: 2911-2920.","journal-title":"J Immunol"},{"key":"503_CR29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1046\/j.1365-2249.1999.00753.x","volume":"115","author":"MF Neurath","year":"1999","unstructured":"Neurath MF, Hildner K, Becker C, et al: Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression. Clin Exp Immunol. 1999, 115: 42-55. 10.1046\/j.1365-2249.1999.00753.x.","journal-title":"Clin Exp Immunol"},{"key":"503_CR30","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1136\/ard.2007.076463","volume":"66","author":"JW Bijlsma","year":"2007","unstructured":"Bijlsma JW, Weinblatt ME: Optimal use of methotrexate: the advantages of tight control. Ann Rheum Dis. 2007, 66: 1409-10. 10.1136\/ard.2007.076463.","journal-title":"Ann Rheum Dis"},{"key":"503_CR31","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1212\/01.WNL.0000032502.89361.0C","volume":"59","author":"A Evoli","year":"2002","unstructured":"Evoli A, Minisci C, Di Schino C, et al: Thymoma in patients with MG: characteristics and long-term outcome. Neurology. 2002, 59: 1844-50.","journal-title":"Neurology"},{"key":"503_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/qjmed\/hcn152","volume":"102","author":"A Chaudhuri","year":"2009","unstructured":"Chaudhuri A, Behan PO: Myasthenic crisis. Q J Med. 2009, 102: 97-107.","journal-title":"Q J Med"},{"key":"503_CR33","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1212\/01.wnl.0000336535.27773.c0","volume":"71","author":"G Gronseth","year":"2008","unstructured":"Gronseth G, French J: Practice parameters and technology assessments: what they are, what they are not, and why you should care. Neurology. 2008, 71: 1639-43. 10.1212\/01.wnl.0000336535.27773.c0.","journal-title":"Neurology"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-11-97.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2377-11-97\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-11-97","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T00:19:21Z","timestamp":1468282761000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/1471-2377-11-97"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,5]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["503"],"URL":"https:\/\/doi.org\/10.1186\/1471-2377-11-97","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,5]]},"article-number":"97"}}